Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director | June 30, 2026 | July 02, 2026 |
| Turnstone Biologics Corp.TSBX · Entity 76646 | Director | June 03, 2024 | July 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29 | Direct | 32,000 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Turnstone Biologics Corp.
Report date June 03, 2024 · Filed July 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2034-06-02 | Direct | 12,770 |
Reported balance
After 2024-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 12,770 · Balance 12,770 F1: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2020 Filed Jun 1, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 1,919 | $20.01 | $38,391.13 |
DisclosureSEC source: 0000899243-20-014721 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,426 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 2,500 | $20.00 | $50,000.00 |
DisclosureSEC source: 0000899243-20-014415 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,345 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 21:24 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | SaleCommon Stock | 2,500 | $20.00 | $50,000.00 |
DisclosureSEC source: 0000899243-20-005300 · doc4.xml · nonDerivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,845 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 21:26 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $16.87 | $0.00 |
DisclosureSEC source: 0000899243-20-002035 · doc4.xml · derivative · entry 1 Gould Robert J · CIK 0001577034 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-01-22 F1 · derivative.exercise_date: This option was granted on January 23, 2020 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2020, subject to continued service. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 21:27 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 107,142 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-19-040968 · a4.xml · derivative · entry 1 Gould Robert J · CIK 0001577034 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,142 Underlying: Common Stock · 107,142 shares Expires 2029-07-17 F1 · derivative.exercise_date: The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments from July 1, 2019 through June 30, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.